Il programma esamina come le caratteristiche del melanoma orientino la scelta delle cure, con attenzione ai biomarcatori, alle terapie immunologiche e mirate, alle…
Riassunto a cura di Smart ECM
Info basate su dati pubblici Agenas. Smart ECM non è responsabile del corso e non ha accordi con il provider che lo organizza. Contattaci
Combining therapies to overcome resistance in melanoma
Il corso affronta la ricerca e la gestione clinica del melanoma, dalle basi biologiche ai biomarcatori, alle terapie immunologiche e mirate. È rivolto a professionisti sanitari coinvolti nella diagnosi e nella cura oncologica e dermatologica.
Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma. The possibility to use targeted and immune -based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of bio markers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma. Melanoma treatment landscape changed with the approval of the first anti -cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF targeted monoclonal antibody, both of which significantly improved overall survival.
Since then, improved understanding of the tumor microenvironment and tumor immunoevasion strategies has resulted in different approaches to target and harness the immune response. Approval of new immune and target therapies has further improved outcomes for patients with advanced melanoma. The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities.
This year latest findings in melanoma research and advances on topics of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the dedicated sessions, focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies. Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.
Tematiche:melanomaimmunoterapia oncologicaterapie a bersaglio molecolarebiomarcatori tumoralimedicina di precisionemelanoma uveale
Il programma dei due giorni
Mer2dicembre
Programma
09:15Introduction and objectivesPaolo A. Ascierto
Session 1 - more translational research in melanoma
09:20Translational data from personalized cancer vaccination trialsRyan Sullivan
09:35MetabolismBradley Isaac Reinfeld
09:50Harnessing CD26hi T cells to mediate potent activity against melanomaChrystal M. Paulos
10:05Harnessing macrophages for anti-cancer therapyJennifer Guerriero
10:20TmeCharles Swanton
10:35Spatial Trans-CriptomicsFlorian Rambow
10:50Genomic approachesTomas Kirchhoff
11:05Discussion on More Translational Research in Melanoma
11:30Coffee Break**
11:45Symposium - The key role of adjuvant therapy in MelanomaPaolo A. Ascierto, Sapna Patel
Great debate
12:35Prediction of therapy outcome: Biological markers VS AI predictive algorithmChristian Blank, Georgina Long
13:00Use of ctDNA monitoring to guide clinical decisions, ready for primetime now: YES or NOReinhard Dummer, Dirk Schadendorf
13:25Lunch**
Session 2 – what have we learned from…
14:15…failed studies?Jeffrey Sosman
14:30…studies ongoing that haven’t read out?Olivier Michielin
14:45…clinical gaps in Melanoma?Omid Hamid
15:00What are we learning with PD-L1/IDO vaccination?James Smithy
15:15…using a common control arm: opportunities and challengesRyan Sullivan
15:30Discussion on What have we learned from…?
15:50SYMPOSIUM Target Therapy in Metastatic MelanomaPaolo A. Ascierto, Reinhard Dummer
16:40SYMPOSIUM Bridging evidence and experience in Metastatic Uveal MelanomaPaolo A. Ascierto
Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trialPaul Nathan
Translating evidence into practice: international experience with tebentafusp in metastatic uveal melanomaEster Simeone
Great debate
17:30Til: frontline vs second lineAllison Betof, Igor Puzanov
17:55Reality Check of Benefits: all Stages vs Advanced StagesAlexander Eggermont, Michael Postow
Gio3dicembre
Programma
Session 3 - emergent strategies
09:15Brain MetastasesHussein Tawbi
09:30Acral MelanomaMitch Levesque
09:45Mucosal MelanomaAlex Shoushtari
10:00Neoadjuvant Study: IPI-NIVO vs NIVO-RELAJanice Mehnert
10:15Toxicities managementDouglas Johnson
10:30Enginereed TILsOlivier Michielin
10:45Discussion on Emergent Strategies
11:00Coffee Break**
11:15Novel MAPK InhibitorRoger Lo
11:30Do we need New Staging?Jeffrey Gershenwald
11:45Not all Immune Checkpoints are created equal: an update on IDOMarc S. Ernstoff
12:00Injectable TherapiesDanielle Bello
12:15Discussion on Emergent Strategies
12:30Lecture - Advancing Cancer Treatment with mRNA: The Evolving Role of Immune ModulationAllison Betof, Hussein A. Tawbi
Great debate
13:00Spatial Biology: YES or NOCarlo Bifulco, Jerome Galon
13:25Quality of Life vs EfficacyOmid Hamid, Paul Nathan
13:50Putting it all together: Practical Considerations for Monday ClinicIgor Puzanov
14:05Conclusion
Dove si svolgerà
Il corso si tiene presso Royal Continental Hotel, Via Partenope 38-42, Napoli.
Quanti crediti ECM ottengo e come arrivano su Co.Ge.A.P.S.?
«Melanoma Bridge» assegna 3,6 crediti ECM al superamento della verifica di apprendimento. I crediti vengono inviati dal provider "Opt S.P.A." al tuo account Co.Ge.A.P.S. dopo la conclusione del corso.
Si svolge online o in presenza?
In presenza: «Melanoma Bridge» si tiene a Via Partenope 38-42, Napoli.
Quanti partecipanti sono previsti per l'evento?
Per «Melanoma Bridge» sono previsti fino a 201 partecipanti.
Quanto pesa questo corso sull'obbligo del triennio 2026-2028?
Con 3,6 crediti, «Melanoma Bridge» copre il 2,4% dei 150 crediti richiesti nel triennio. Con l'esonero o la riduzione per chi ha completato il triennio precedente la quota sale.
A quale obiettivo formativo corrisponde questo evento?
«Melanoma Bridge» ha come obiettivo formativo "Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere", parte degli "Obiettivi formativi tecnico-professionali".
Quali competenze si acquisiranno durante l'evento?
Al termine di «Melanoma Bridge»:
Advances in understanding the genetic and somatic alterations of melanoma have led to a rapidly evolving therapeutic landscape. targeted therapies and immunotherapies, used alone, in combination, or sequentially, aim to improve treatment responses, overcome resistance, and enhance immune activity.
the introduction of ctla-4 checkpoint inhibitors and braf-targeted therapies marked a major breakthrough, significantly improving overall survival. further insights into the tumor microenvironment and immune evasion mechanisms have driven the development of new immunomodulatory and targeted approaches.
current research focuses on:
- biomarkers and precision medicine to predict treatment response;
- combination strategies involving immunotherapy, targeted therapies, and other treatment modalities;
- advances in melanoma prevention, diagnosis, and treatment;
- expert debates on current controversial issues in melanoma management
Si tratta di un evento residenziale interattivo?
No, «Melanoma Bridge» non è un evento residenziale interattivo.
Quali metodi di insegnamento sono utilizzati nell'evento?
In «Melanoma Bridge» i metodi didattici previsti sono: serie di relazioni su tema preordinato.
L'evento si terrà in italiano?
No, «Melanoma Bridge» non si terrà esclusivamente in italiano.
Come funziona la verifica di presenza?
In «Melanoma Bridge» la presenza viene verificata tramite firma di presenza.
Come funziona la verifica di apprendimento?
In «Melanoma Bridge» la verifica dell'apprendimento avviene tramite questionario a risposta multipla.
Posso sommare più corsi di Opt S.P.A.?
Sì: oltre a «Melanoma Bridge» puoi seguire tutti i corsi che vuoi di Opt S.P.A., non c'è un limite per provider.
